Additional application of single-cell sequencing, multiplex fluorescence, and developing technologies which enable spatial resolution of cell identities, functional states, and gene expression in cellular niches within the TME of diverse clinical ER+ breast cancers at the primary and different metastatic sites, especially bone, will illuminate the underlying biology. This evidence concerns the gene ESR1 and breast cancer.